Mauro Niso

Prof. Dr. Mauro Niso

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NCNicola Antonio Colabufo
Nicola Antonio Colabufo
FBFrancesco Berardi
Francesco Berardi
MCMariangela Cantore
Mariangela Cantore
Marialessandra ContinoMarialessandra Contino
Marialessandra Contino
CICarmela Inglese
Carmela Inglese
RPRoberto Perrone
Roberto Perrone

1 July 2006 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
Amalia AzzaritiAmalia Azzariti
Amalia Azzariti
NCNicola A. Colabufo
Nicola A. Colabufo
FBFrancesco Berardi
Francesco Berardi
LPLetizia Porcelli
Letizia Porcelli
MNMauro Niso
Mauro Niso
APAngelo Paradiso
Angelo Paradiso
σ Ligands have recently been shown to have cytotoxic activity, to induce ceramide-dependent/caspase-independent apoptosis, and to down-regulate P-glycoprotein (P-gp) mRNA levels in some mouse and human models. In this study, we verified whether a mixed σ2 agonist/σ1 antagonist, PB28, was able to have antitumor activity and to enhance anthracycline efficacy in two human breast cancer cell lines, MCF7 and MCF7 ADR, both characterized by significant σ2 receptor expression, by high and low σ1 receptor expression, and low and high P-gp expression, respectively. In both cell lines, PB28 showed high σ2 receptor affinity and low σ1 receptor affinity; furthermore, it inhibited cell growth with a clear effect at 48 hours (IC50 in nanomolar range), a consistent time exposure-independent increase of G0-G1-phase fraction (of ∼20% of both cell lines) and caspase-independent apoptosis (15% increased after 1-day drug exposure). PB28 also reduced P-gp expression in a concentration- and time-dependent manner (∼60% in MCF7 and 90% in MCF7 ADR). We showed also a strong synergism between PB28 and doxorubicin by adopting either simultaneous or sequential schedules of the two drugs. We suggest that this synergism could depend on PB28-induced increase of intracellular accumulation of doxorubicin (∼50% in MCF7 and 75% in MCF7 ADR by flow cytometry analysis). In conclusion, we suggest that the σ2 agonist PB28 could be an interesting antitumor agent either in monotherapy or in combination with conventional drugs. [Mol Cancer Ther 2006;5(7):1807–16]

31 July 2004 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
NCNicola Antonio Colabufo
Nicola Antonio Colabufo
FBFrancesco Berardi
Francesco Berardi
Marialessandra ContinoMarialessandra Contino
Marialessandra Contino
MNMauro Niso
Mauro Niso
CACarmen Abate
Carmen Abate
VTVincenzo Tortorella
Vincenzo Tortorella

1 January 2008 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
NCNicola Antonio Colabufo
Nicola Antonio Colabufo
FBFrancesco Berardi
Francesco Berardi
MCMariangela Cantore
Mariangela Cantore
Maria Grazia PerroneMaria Grazia Perrone
Maria Grazia Perrone
Marialessandra ContinoMarialessandra Contino
Marialessandra Contino
APAngelo Paradiso
Angelo Paradiso

1 July 2015 in European Journal of Pharmacology
Verified
Journal Article
Closed access
CACarmen Abate
Carmen Abate
MNMauro Niso
Mauro Niso
VIVittoria Infantino
Vittoria Infantino
Alessio MengaAlessio Menga
Alessio Menga
FBFrancesco Berardi
Francesco Berardi

1 February 2009 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
NCNicola A. Colabufo
Nicola A. Colabufo
FBFrancesco Berardi
Francesco Berardi
Marialessandra ContinoMarialessandra Contino
Marialessandra Contino
MNMauro Niso
Mauro Niso
RPRoberto Perrone
Roberto Perrone
Pharmacokinetic limitations affect drug bioavailability determining the loss or the reduction of the pharmacological effects. The Gastro Intestinal tract (GI) and the Blood Brain Barrier (BBB) are the most important restrictive and selective physiological lines of defense of the organism. Although several parameters such as LogP, LogD and Ka have been extensively employed for determining drug bioavailability, the active transports, present in these biological barriers, play an important role for dosing and limiting cell drugs concentration. In particular, ATP Binding Cassette (ABC) transporters are involved in the active transport both in GI and BBB. Their strategic activity and biochemical and pharmacological role are herein treated.